Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Apr 17, 2024
|
PDF Version
Read More
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 26, 2024
|
PDF Version
Read More
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
Mar 20, 2024
|
PDF Version
Read More
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
Mar 13, 2024
|
PDF Version
Read More
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
Mar 12, 2024
|
PDF Version
Read More
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Mar 06, 2024
|
PDF Version
Read More
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
Feb 29, 2024
|
PDF Version
Read More
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
Feb 07, 2024
|
PDF Version
Read More
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
Jan 03, 2024
|
PDF Version
Read More
Print Page
Print Page
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?

 

Yes
No